Mathew Blackman

Stock Analyst at Stifel

(1.42)
# 1795
Out of 5,380 analysts
69
Total ratings
Success rate
Average return
17 Stocks
Name Action PT Current % Upside Ratings Updated
INGN Inogen
Maintains: Hold
10 7
6.97 0.43% 12 May 8, 2025
TNDM Tandem Diabetes Care
Maintains: Buy
60 31
19.26 60.96% 6 May 1, 2025
PEN Penumbra
Maintains: Strong Buy
301 318
253.41 25.49% 2 Apr 24, 2025
CLPT ClearPoint Neuro
Maintains: Strong Buy
19 25
11.29 121.43% 3 Apr 1, 2025
BBNX Beta Bionics
Initiates Coverage On: Buy
25
15.4 62.34% 1 Feb 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
245 293
305.26 -4.02% 5 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
92 94
58.49 60.71% 5 Feb 21, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
18 24
10.8 122.22% 5 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
6 3
1.34 123.88% 1 Oct 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Hold
50
n/a n/a 1 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
90 100
86.14 16.09% 11 Aug 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
19 16
11.21 42.73% 5 Aug 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
18 11
9.02 21.95% 4 May 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
10
n/a n/a 3 Jan 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
18 16
n/a n/a 2 Mar 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
64
n/a n/a 1 Oct 20, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
30
n/a n/a 2 Aug 26, 2020